Skip to main content
PAHC
NASDAQ Life Sciences

Controlling Shareholder Establishes New $24.9M Stock Sale Plan

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
8
Price
$33.26
Mkt Cap
$1.349B
52W Low
$22.51
52W High
$60.08
Market data snapshot near publication time

summarizeSummary

A controlling shareholder has initiated a new Rule 10b5-1 plan to sell up to $24.9 million in stock, adding to recent sales and indicating ongoing insider distribution.


check_boxKey Events

  • New 10b5-1 Sales Plan Established

    Jack C. Bendheim's entity, BFI Co., LLC, adopted a new Rule 10b5-1 plan to sell up to 750,000 shares of Class A Common Stock through March 2027, with sales commencing in September 2026.

  • Significant Future Selling Pressure

    The shares covered by the new plan are valued at approximately $24.9 million, representing about 1.85% of the company's current market capitalization, indicating a substantial future overhang.

  • Ongoing Insider Sales

    The filing also disclosed additional sales of 39,728 shares between April 28 and May 7, 2026, totaling approximately $2.56 million, continuing a trend of distribution by the controlling shareholder.

  • Controlling Stake Maintained

    Despite the sales and future plan, Jack C. Bendheim and BFI Co., LLC will continue to beneficially own a controlling stake of approximately 48.2% of the company's common stock.


auto_awesomeAnalysis

Jack C. Bendheim, a controlling shareholder, has established a new Rule 10b5-1 plan to sell up to 750,000 shares, valued at approximately $24.9 million based on current prices. This plan, set to begin in September 2026, signals a significant future selling pressure from a major insider. The filing also reports additional sales of approximately $2.56 million since the last amendment, continuing a pattern of distribution by the insider.

At the time of this filing, PAHC was trading at $33.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $22.51 to $60.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed PAHC - Latest Insights

PAHC
May 22, 2026, 4:24 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
PAHC
May 06, 2026, 4:44 PM EDT
Source: Reuters
Importance Score:
8
PAHC
May 06, 2026, 4:39 PM EDT
Filing Type: 8-K
Importance Score:
8
PAHC
May 06, 2026, 4:25 PM EDT
Filing Type: 10-Q
Importance Score:
8
PAHC
Apr 30, 2026, 4:26 PM EDT
Source: Wiseek News
Importance Score:
8
PAHC
Apr 27, 2026, 4:43 PM EDT
Filing Type: 8-K
Importance Score:
7
PAHC
Apr 23, 2026, 8:36 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
PAHC
Feb 04, 2026, 4:41 PM EST
Filing Type: 8-K
Importance Score:
8
PAHC
Feb 04, 2026, 4:16 PM EST
Filing Type: 10-Q
Importance Score:
8